DEALS ANALYSIS
Deals activity: Global deals increase YoY; private equilty deals soar
Powered by
Deals activity by geography
Medical industry deals, as captured by GlobalData’s Medical Intelligence Centre, are up year-on-year (YoY) across the majority of regions.
North America is leading in terms of deal value, but recorded the second lowest YoY growth in deals volume at 9%. Asia-Pacific, ranking third in terms of deal value, has seen the biggest YoY change, with deal volumes increasing by 35%.
The volume of deals recorded by GlobalData also increased YoY in Europe (20%) and Middle East and Africa (28%), but declined in South and Central America (6%).
Deals activity by type
| Deal type | Total deals value ($m) | Total deal count | YoY change (volume) |
| Venture Financing | 153,550 | 17,281 | 68 |
| Partnership | 14,985 | 10,887 | 104 |
| Equity Offering | 391,558 | 8,452 | 215 |
| Acquisition | 2,046,156 | 7,396 | -15 |
| Debt Offering | 1,130,694 | 2,479 | -11 |
| Asset Transaction | 100,065 | 1,831 | -27 |
| Private Equity | 294,237 | 1,772 | 264 |
| Grant | 155,064 | 569,410 | 18 |
| Licensing Agreement | 6,608 | 687 | 45 |
| Merger | 171,060 | 313 | 49,240 |
A breakdown of deals by type and volume shows a 49,240% growth in mergers YoY, while acquisitions are down 15%, partnerships are up 104% and asset transactions are down 27%. Financing deals have increased across some types, with venture financing up 68% YoY and equity offerings up 215%, while debt offerings are down 11%.
Private equity has grown by 264% in number of deals YoY, while the number of grants recorded is up 18%.
Deals activity by therapy area
A notable development apparent in GlobalData’s analysis of medical industry deals by therapy area is the increase of in vitro diagnostics deals. After remaining relatively steady, the number of recorded in vitro diagnostics deals increased significantly in 2019/20. This is likely due to demand caused by the ongoing Covid-19 pandemic.
Note: All numbers as of 01 May 2021. Deals captured by GlobalData cover M&As, strategic alliances, various types of financing and contract service agreements.
For more insight and data, visit GlobalData's Medical Intelligence Centre
Latest deals in brief
DispatchHealth acquires mobile imaging firm Professional Portable X-Ray
DispatchHealth has acquired mobile imaging company Professional Portable X-Ray to offer imaging services when needed for home visit patients. The latest deal will aid DispatchHealth in continuing to build its in-home care system by expanding its existing service specialities to include mobile radiology.
DJO acquires MedShape to expand foot and ankle business
Colfax subsidiary DJO has acquired orthopaedic medical device company MedShape to expand its foot and ankle business as well as add advanced shape memory technologies to its portfolio.
Vicarious Surgical sign business combination agreement with D8 Holdings
Vicarious Surgical has signed a definitive business combination agreement with special purpose acquisition company D8 Holdings worth up to a total of approximately $1.1bn. The deal is anticipated to provide up to $460m of gross proceeds, including up to $345m of cash held in D8’s trust account.
Endologix acquires PQ Bypass to expand vascular product portfolio
Deerfield Management owned Endologix has acquired medical technology company PQ Bypass to bolster vascular reach to treat unmet medical needs of both abdominal aortic aneurysm and peripheral arterial disease patients.
Imageens raises funds to launch first two products
Medical artificial intelligence start-up Imageens has secured $1.4m (€1.2m) in seed financing to launch its first two products. The funding round was led by Anaxago with participation from Business Angels ds Grandes Ecoles, Coalescence and existing investors of Imageens.
Italy’s DiaSorin to buy Luminex in $1.8bn deal
Italian diagnostics firm DiaSorin has agreed to buy US rival Luminex for around $1.8bn. The takeover will give DiaSorin control of a multiplex infectious disease testing system, a platform for running up to 12 in vitro diagnostics in parallel and allow it to expand its footprint in the US.
